By Deena Beasley
Feb 23 (Reuters) – Despite the backdrop of a world struggling with economic instability, pharmaceutical companies unfurled prices for new U.S. drugs at a staggering 35% hike in 2023, outpacing the previous year. This seismic surge underlines the industry’s gravitation towards exorbitant therapeutics for conditions such as muscular dystrophy, accentuating an unmistakable reality: the cost of novel medications continues to climb skyward.
The median annual list price for a new drug in the U.S. hit $300,000 in 2023, according to a comprehensive Reuters analysis of 47 medicines. This figure reflects a steep ascent from the $222,000 tag per annum documented a mere year prior. Furthemore, an in-depth study published in JAMA documented that the median annual price stood at $180,000 back in 2021 for the first 30 drugs brought to market through mid-July.
Shift Towards Rare Diseases
A notable facet of the burgeoning pharmaceutical landscape is the introduction of more than half of the new products approved by the Food and Drug Administration in 2023 and 2022 for orphan diseases, which afflict fewer than 200,000 Americans. Significantly, this marks an escalation from the 49% seen in the previous five years.
Critic’s Perspective
Dan Ollendorf, the chief scientific officer at the Institute for Clinical and Economic Review (ICER), laments the unchecked ascent of drug prices. He argues that several rare disease and cancer drugs are seemingly not priced commensurate with their therapeutic value. Ollendorf contends that a dearth of alternatives has bestowed manufacturers with undue bargaining power, thereby sanctioning the unfettered escalation in drug prices.
Influence of Market Dynamics
Of the 47 medications subjected to the analysis, the highest price for drugs that necessitate consistent usage was a staggering $1.8 million annually for Regeneron’s Veopoz, designed for CHAPLE disease, an exceedingly rare inherited condition. Contrastingly, the floor price was a minuscule $576 for the diabetes drug Brenzavvy sold through TheracosBio in partnership with Mark Cuban’s Cost Plus Drugs online pharmacy.
Pharma Market Dynamics
A noteworthy dimension pertains to gene therapies, which represent one-time treatments. These range in price from $2.2 million for Casgevy, a sickle cell disease treatment crafted by Vertex and CRISPR, to Sarepta’s muscular dystrophy therapy Elevydis, commanding an eye-watering price of $3.2 million. Aligned with this, the U.S. bestows upon drug manufacturers market exclusivity, fee waivers, direct funding for research and development, and tax credits for such orphan treatments.
“The hope is that eventually we will see some therapeutic competition in this space and bring prices down,” expressed Dana Goldman, director of the USC Schaeffer Center for Health Policy & Economics, highlighting and underlying the urgent necessity for an equilibrium vis-a-vis pricing and therapeutic innovation.
Economic Impact and Beyond
As patents expire, lower-cost generics are poised to alleviate prescription drug price inflation, which, over the course of 12 months through December, remained roughly in-sync with broader inflation at 3.3%, accordant to U.S. government data indicating the fluid dynamics steering the pharmaceutical industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
